OPKO Health Inc primarily operates in the biotechnology and pharmaceutical industries.

Some of the main competitors of OPKO Health Inc in the market include companies such as AbbVie Inc, Thermo Fisher Scientific Inc, and Quest Diagnostics Incorporated.

OPKO Health Inc is a biopharmaceutical and diagnostics company that focuses on developing diagnostic tests and pharmaceutical products for various medical conditions. Founded in 1991, the company has grown to become a leading player in the healthcare industry. OPKO Health Inc has a diverse portfolio of products and services, including point-of-care diagnostics, molecular diagnostics, and pharmaceuticals for the treatment of conditions such as prostate cancer, metabolic disorders, and ophthalmic diseases. With its strong emphasis on research and development, OPKO Health Inc remains committed to improving patient outcomes and providing innovative solutions in the field of healthcare.

OPKO Health Inc has achieved several significant milestones. Some of these include the FDA approval of its RECORLEV™ (levoketoconazole) drug for the treatment of endogenous Cushing's syndrome, a rare hormonal disorder. The company also received FDA approval for its RAYALDEE® (calcifediol) extended-release capsules for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. Furthermore, OPKO Health Inc has made advancements in its diagnostics segment through the development of proprietary molecular diagnostic tests for various diseases. These achievements showcase OPKO Health Inc's commitment to innovation and improving healthcare outcomes.

OPKO Health Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered in Miami, Florida. Additionally, OPKO Health Inc has a significant presence in Chile, where it operates a subsidiary known as OPKO Chile. The company also has operations and partnerships in Israel, Mexico, and Ireland. With its global presence, OPKO Health Inc continues to expand its reach and make advancements in the healthcare industry across various markets.

OPKO Health Inc represents a commitment to advancing patient care and creating innovative solutions in healthcare. With a focus on precision medicine, the company strives to improve diagnostic testing and develop therapeutic treatments across various disease areas. OPKO Health Inc values scientific excellence, collaboration, and continuous innovation to enhance patient outcomes. By leveraging cutting-edge technologies and expertise, the company aims to address unmet medical needs and make a positive impact on global healthcare. Through its dedication to research and development, OPKO Health Inc is dedicated to improving the quality of life for individuals worldwide.

Analysts currently set an average price target of 3,63 USD for the OPKO Health stock (median: 3,06 USD), implying +161,1 % versus the latest price. The consensus is based on 11 analyst ratings.

OPKO Health Analyytikkojen kursstavoitteet 2026

11 analysts currently rate the OPKO Health stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect OPKO Health to generate revenue of 536,80 M USD and earnings per share of −0,30 USD.

OPKO Health Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the OPKO Health share trades at 1,21 EUR (1,39 USD).

The OPKO Health share (OPK) is listed on 8 stock exchanges, including: NASDAQ (OPK), Frankfurt (XCY.F), München (XCY.MU), Düsseldorf (XCY.DU), London (0KCS.L), London (0KCS.L), SIX (Zürich) (XCY.SW).

OPKO Health Inc is a diversified healthcare company focused on a wide range of diagnostic, pharmaceutical, and biotechnology products and services. The company was founded in 1991 and is headquartered in Miami, Florida. The business model of OPKO is to offer innovative diagnostic and therapeutic solutions for a variety of diseases. The company operates various business segments, including diagnostics and pharmaceuticals, biotechnology, and research and development. Diagnostics and Pharmaceuticals: OPKO is a leading provider of medical diagnostic tests, including PSA tests for prostate cancer, 4KScore for aggressive prostate cancer, and Claros 1 for rapid diagnosis of heart disease. The company also offers a wide range of pharmaceutical products for the treatment of diseases such as hemophilia, growth hormone deficiency, and low testosterone. Biotechnology: OPKO owns and operates a variety of biotechnology companies and related product lines. DemosRx produces and distributes drugs for ophthalmology and dermatology, while Bio-Reference Laboratories provides medical testing and services for physicians and clinics, supporting their patients through a wide range of pathology tests. The combination of these two diagnostic units is intended to provide hospitals with a more comprehensive second opinion in diagnosis, particularly for patients who benefit from second opinions, recognized expert opinions, or patients removed from Soliris. Research and Development: OPKO invests significant sums in research and development of new medical technologies and drugs. The company has research projects in the areas of oncology, ophthalmology, obstetrics and gynecology, neurology, and gastroenterology. Some of OPKO's key projects include the development of drugs for the treatment of Alzheimer's, autism, osteoporosis, and diabetes. OPKO Health Inc aims to offer innovative solutions to patients and medical professionals worldwide. The company builds on its position as a leading provider of diagnostic products and services and is committed to translating innovative research findings into new drugs and therapies. Overall, OPKO Health Inc is a leading provider of medical diagnostic tests, pharmaceutical products, and biotechnology solutions with the goal of improving the lives of patients worldwide.

odotettu liikevaihto OPKO Health on 536,80 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto OPKO Health on −227,84 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

OPKO Health:n hinta-voitto-suhde (P/E) on tällä hetkellä −4,67. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan OPKO Health-osakkeen arvostusta.

OPKO Health:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,98. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii OPKO Health-osakkeen arvostuskennuslukuna.

OPKO Health:n Eulpool-laatuscore on 1/10.

OPKO Health:n ISIN on US68375N1037. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

OPKO Health:n WKN on A0MUUJ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

OPKO Health:n ticker on OPK. Tämä pörssinoteeraus käytetään OPKO Health-osakkeiden kauppaan pörssissä.

OPKO Health maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

OPKO Health kuuluu sektoriin 'Terveydenhuolto'.

OPKO Health:n osingot jaetaan valuutassa USD.